Treatment for relapsed or refractory chronic lymphocytic leukaemia: an ongoing challenge

被引：1
作者：
Strati, Paolo [1 ]
机构：
[1] Univ Texas Houston, MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
来源：
LANCET HAEMATOLOGY | 2017年 / 4卷 / 03期
关键词：
IDELALISIB; FLUDARABINE; RITUXIMAB;
D O I：
10.1016/S2352-3026(17)30020-0
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E97 / E98
页数：2
相关论文
共 50 条
  • [31] A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia
    Haines, I.
    Elliott, P.
    Stanley, R.
    INTERNAL MEDICINE JOURNAL, 2009, 39 (04) : 269 - 271
  • [32] Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study
    Iannitto, Emilio
    Morabito, Fortunato
    Mancuso, Salvatrice
    Gentile, Massimo
    Montanini, Antonella
    Augello, Accursio
    Bongarzoni, Velia
    D'Arco, Alfonso
    Di Renzo, Nicola
    Fazzi, Rita
    Franco, Giovanni
    Marasca, Roberto
    Mule, Antonino
    Musso, Maurizio
    Musto, Pellegrino
    Pennese, Elsa
    Piccin, Andrea
    Rota-Scalabrini, Delia
    Visani, Giuseppe
    Rigacci, Luigi
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 (03) : 351 - 357
  • [33] How I treat patients with relapsed chronic lymphocytic leukaemia
    Cuthill, Kirsty
    Devereux, Stephen
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (04) : 423 - 435
  • [34] Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies
    Rainone, Michael
    Siddiqi, Tanya
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2022, 17 (01) : 39 - 45
  • [35] Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia
    Molica, Stefano
    Montserrat, Emili
    LANCET HAEMATOLOGY, 2019, 6 (02): : E65 - E66
  • [36] Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Schetelig, Johannes
    Coutre, Steven
    Seymour, John F.
    Munir, Talha
    Puvvada, Soham D.
    Wendtner, Clemens-Martin
    Roberts, Andrew W.
    Jurczak, Wojciech
    Mulligan, Stephen P.
    Boettcher, Sebastian
    Mobasher, Mehrdad
    Zhu, Ming
    Desai, Monali
    Chyla, Brenda
    Verdugo, Maria
    Enschede, Sari Heitner
    Cerri, Elisa
    Humerickhouse, Rod
    Gordon, Gary
    Hallek, Michael
    Wierda, William G.
    LANCET ONCOLOGY, 2016, 17 (06) : 768 - 778
  • [37] Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?
    Cuneo, Antonio
    Foa, Robin
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2019, 11
  • [38] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [39] Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
    Eyre, Toby A.
    Lamanna, Nicole
    Roeker, Lindsey E.
    Ujjani, Chaitra S.
    Hill, Brian T.
    Barr, Paul M.
    Lansigan, Erick
    Cheson, Bruce D.
    Yazdy, Maryam
    Allan, John N.
    Rhodes, Joanna
    Schuster, Stephen J.
    Nabhan, Chadi
    Skarbnik, Alan
    Leslie, Lorie
    Islam, Prioty
    Whitaker, Katherine
    Coombs, Catherine C.
    Tuncer, Hande H.
    Pagel, John M.
    Jacobs, Ryan
    Winter, Allison M.
    Bailey, Neil
    Sitlinger, Andrea
    Schuh, Anna H.
    Follows, George
    Fox, Christopher P.
    Brander, Danielle M.
    Shadman, Mazyar
    Mato, Anthony R.
    HAEMATOLOGICA, 2021, 106 (01) : 284 - 287
  • [40] Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib
    Machnicki, Marcin M.
    Gorniak, Patryk
    Pepek, Monika
    Szymczyk, Agnieszka
    Iskierka-Jazdzewska, Elzbieta
    Steckiewicz, Pawel
    Bluszcz, Aleksandra
    Rydzanicz, Malgorzata
    Hus, Marek
    Ploski, Rafal
    Makuch-Lasica, Hanna
    Nowak, Grazyna
    Juszczynski, Przemyslaw
    Jamroziak, Krzysztof
    Stoklosa, Tomasz
    Pula, Bartosz
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2021, 106 (03) : 320 - 326
12345